Pharmacyclics, Inc. (NASDAQ:PCYC) announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) …
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
In a research report issued today, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ:PCYC) with a price target of …
This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with a few insights on Pharmacyclics, Inc. (NASDAQ:PCYC), following the release of the company’s fourth-quarter results, posting GAAP net …
In a research report published Tuesday, BTIG analyst Hartaj Singh maintained a Buy rating on Pharmacyclics (NASDAQ :PCYC) with a $225 price target, …
Pharmacyclics, Inc. (NASDAQ:PCYC) today provided its preliminary unaudited 2014 U.
In a research report released Monday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price target of …
In a research report sent to investors today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a price …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Pharmacyclics (NASDAQ:PCYC) with a $188 price target, following the company third-quarter results, posting diluted GAAP EPS …
